The prevention of ischemic stroke with antithrombotic drugs

被引：0

作者：

Perko, Denis ^{[1
]}

Zaletel, Marjan ^{[1
]}

机构：

[1] Univ Klin Ctr Ljubljana, Klin Oddelek Vaskularno Nevrologijo Intenzivno Ne, Ljubljana, Slovenia

来源：

ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL | 2012年 / 81卷 / 02期

关键词：

ischemic stroke; antiplatelet drugs; anticoagulants; LOW-DOSE ASPIRIN; PATENT FORAMEN OVALE; ATRIAL-FIBRILLATION; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; CEREBRAL INFARCTION; VASCULAR EVENTS; PLATELET REACTIVITY; RANDOMIZED-TRIAL;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Current antithrombotic drugs reduce the risk of stroke, heart attack and death from vascular causes by 25 % in patients with cerebral ischemic events resulting from disease of small or large cerebral arteries. In the primary prevention, Acetylsalicylic acid (ASA) reduces the risk of stroke by 19 % in women but not in men. In patients with nonvalvular atrial fibrillation the risk of stroke treating with ASA is reduced by 20 %. Oral anticoagulants significantly reduce stroke risk due to nonvalvular atrial fibrillation by 65-70 % compared with placebo and by 40 % compared with ASA alone. At the same time they cause more major bleedings. Recently studied new antiplatelet drugs and anticoagulants might alter the current course of stroke prevention treatment. Research is also needed on the benefits and risks of combination antiplatelets and anticoagulants in patients with nonvalvular atrial fibrillation in combination with arterial cerebral disease.

引用

页码：128 / 138

页数：11

共 68 条

[11] Rationale and Design of a Randomized, Double-Blind, Parallel-Group Study of Terutroban 30 mg/day versus Aspirin 100 mg/day in Stroke Patients: The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study [J].

Bousser, M. G. ;

Amarenco, P. ;

Chamorro, A. ;

Fisher, M. ;

Ford, I. ;

Fox, K. ;

Hennerici, M. G. ;

Mattle, H. P. ;

Rothwell, P. M. .

CEREBROVASCULAR DISEASES, 2009, 27 (05) :509-518

[12]

Calif R, 2010, AM HEART ASS SCI SES

[13]

Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]

[14] Aspirin dose for the prevention of cardiovascular disease - A systematic review [J].

Campbell, Charles L. ;

Smyth, Susan ;

Montalescot, Gilles ;

Steinhubl, Steven R. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :2018-2024

[15] Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis [J].

Chimowitz, MI ;

Lynn, MJ ;

Howlett-Smith, H ;

Stern, BJ ;

Hertzberg, VS ;

Frankel, MR ;

Levine, SR ;

Chaturvedi, S ;

Kasner, SE ;

Benesch, CG ;

Sila, CA ;

Jovin, TG ;

Romano, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (13) :1305-1316

[16] Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].

Connolly, S. ;

Pogue, J. ;

Hart, R. ;

Pfeffer, M. ;

Hohnloser, S. ;

Chrolavicius, S. ;

Yusuf, S. .

LANCET, 2006, 367 (9526) :1903-1912

[17] Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation [J].

Connolly, S. J. ;

Yusuf, S. ;

Camm, J. ;

Chrolavicius, S. ;

Commerford, P. ;

Flather, M. ;

Hart, R. G. ;

Hohnloser, S. H. ;

Joyner, C. ;

Pfeffer, M. ;

Gaudin, C. ;

Blumenthal, M. ;

Marchese, C. ;

Pogue, J. ;

Hart, R. ;

Hohnloser, S. ;

Anand, I. ;

Arthur, H. ;

Avezum, A. ;

Budaj, A. ;

Ceremuzynski, L. ;

De Caterina, R. ;

Diaz, R. ;

Dorian, P. ;

Flaker, G. ;

Fox, K. A. A. ;

Franzosi, M. G. ;

Goldhaber, S. ;

Golitsyn, S. ;

Granger, C. ;

Halon, D. ;

Hermosillo, A. ;

Hunt, D. ;

Jansky, P. ;

Karatzas, N. ;

Keltai, M. ;

Kozan, O. ;

Lanas, F. ;

Lau, P. ;

Le Heuzey, J. Y. ;

Lewis, B. S. ;

Morais, J. ;

Morillo, C. ;

Paolasso, E. ;

Peters, R. J. ;

Pfisterer, M. ;

Piegas, L. ;

Pipilis, A. ;

Sitkei, E. ;

Swedberg, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (20) :2066-2078

[18] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[19] Triflusal for preventing serious vascular events in people at high risk [J].

Costa, Joao ;

Ferro, Jose M. ;

Matias-Guiu, Jordi ;

Alvarez-Sabin, Jose ;

Torres, Ferran .

STROKE, 2006, 37 (08) :2193-2195

[20] Triflusal vs aspirin for prevention of cerebral infarction -: A randomized stroke study [J].

Culebras, A ;

Rotta-Escalante, R ;

Vila, J ;

Domínguez, R ;

Abiusi, G ;

Famulari, A ;

Rey, R ;

Bauso-Tosselli, L ;

Gori, H ;

Ferrari, J ;

Reich, E .

NEUROLOGY, 2004, 62 (07) :1073-1080

← 1 2 3 4 5 6 7 →